医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Macrogen Launches Special Promotion on Exome Sequencing

2015年08月10日 PM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

The precision medicine biotech company Macrogen (CEO Chong Hyon-yong, www.macrogen.com) (KOSDAQ:038290), announced on August 10th that it is launching a special promotion on exome sequencing.

During this special promotion period, Macrogen will offer exome sequencing service with 100x coverage using SureSelect Human All Exome V4 (51M) or V5 (50M) capture kit at special price of $399 per sample.

Researchers around the world can take advantage of this Whole Exome Sequencing (WES) service on very special price terms. The WES service is characterized by efficient large data generation and fast Turnaround Time (TAT) that are based on the industry’s best next-generation sequencing service of Macrogen as well as its professional service know-hows.

To date, Macrogen has successfully provided the WES service for more than 35,000 human samples to customers around the world. In particular, Macrogen has recently achieved the capability of offering a world-class Exome Sequencing service, enabling it to sequence more than 10,000 human exomes per month, and over a maximum of 120,000 per year through the introduction of new platforms and upgrade of existing platforms.

By targeting and sequencing only the protein coding regions, which accounts for less than 2% of the entire genome, Exome Sequencing provides a cost efficient alternative to Whole Genome Sequencing (WGS). The researchers can efficiently conduct comparative sequencing research on large population samples by increasing the number of sequencing samples.

Macrogen CEO Chong Hyon-yong said, “This Exome Project Special Promotion has been planned to further strengthen Macrogen’s customer-centered service philosophy, which we have adhered to for the past 20 years or so to provide the best customer service through high-quality data, fast delivery, and competitive prices.” He also added that “Macrogen is also planning various other promotions to support the research activities of global researchers in the near future.”

For further details on this promotion, refer to http://dna.macrogen.com/eng/support/event/event_view.jsp?board_number=22359&trace=genomeweb150804, and for details on service and ordering, please contact ngs@macrogen.com.

About Macrogen

Macrogen, Inc. (www.macrogen.com), based in Seoul, Korea, is a world leading service provider in high-quality gene analysis and has enjoyed stable and steady growth since 1997. Macrogen Inc. has been dedicated to provide a reliable and efficient service of DNA Sequencing and bioinformatics with profound knowledge and unbeatable amount of experience over 17 years. The company’s diverse offerings include DNA sequencing, next generation sequencing, microarray analysis, oligonucleotide synthesis, DNA chip and genetically engineered mice services. We serve over +17,000 customers from academic research and industry in 120 countries around the globe and have subsidiary companies in USA, Japan and Europe, headquartered in South Korea. Find out more at http://www.macrogen.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150810005073/en/

CONTACT

Macrogen Inc.
Yonghwan Kang, +82-2-2113-7113
snatch@macrogen.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持